0000000000855803

AUTHOR

Sandra Trapani

0000-0003-1105-1500

showing 2 related works from this author

COVID-19 in Infants Less than 3 Months: Severe or Not Severe Disease?

2022

Abstract: Compared to adults, severe or fatal COVID-19 disease is much less common in children. However, a higher risk for progression has been reported in infants. Different pediatric COVID-19 severity scores are reported in the literature. Methods: Subjects under 90 days of age admitted to 35 Italian institutions for COVID-19 were included. The severity of COVID-19 was scored as mild/moderate or severe/critical following the classification reported in the literature by Venturini, Dong, Kanburoglu, and Gale. To assess the diagnostic accuracy of each classification system, we stratified all enrolled patients developing a posteriori severity score based on clinical presentation and outcomes…

AdultFeverCOVID-19.SARS-CoV-2infantsSARS-CoV-2; COVID-19; neonates; infantsCOVID-19; SARS-CoV-2; infants; neonatesInfant NewbornCOVID-19infantneonatesInfectious DiseasesCoughVirologyHumansneonateChildHumanViruses; Volume 14; Issue 10; Pages: 2256
researchProduct

Sensitivity of three commercial tests for SARS-CoV-2 serology in children: an Italian multicentre prospective study

2022

Abstract Background US Food and Drug Administration has issued Emergency Use Authorizations for hundreds of serological assays to support Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) diagnosis. The aim of this study is to evaluate, for the first time in children, the performance of three widely utilized SARS-CoV-2 serology commercial assays, Diesse Diagnostics (IgG, IgA, IgM) and Roche Diagnostics, both Roche Nucleocapsid (N) IgG and Roche Spike (S) IgG assays. Methods Sensitivity and 95% confidence intervals (CIs) were estimated for each of the three different serological tests and mixed and direct comparison were performed. Univariate and multivariate Poisson regression mo…

SARS-CoV-2COVID-19; Children; Electrochemiluminescent immunoassay (ECLIA); Enzyme-linked immunosorbent assay (ELISA); SARS-CoV-2Electrochemiluminescent immunoassay (ECLIA)Enzyme-linked immunosorbent assay (ELISA)COVID-19General MedicineUnited StatesImmunoglobulin AImmunoglobulin MImmunoglobulin GCOVID-19 Children Electrochemiluminescent immunoassay (ECLIA) Enzyme-linked immunosorbent assay (ELISA) SARS-CoV-2HumansProspective StudiesChildChildren
researchProduct